Precigen rises after US FDA approves immunotherapy for rare respiratory disease

** Shares of drugmaker Precigen PGEN.O jump 82.2% to $3.37 premarket

** U.S. FDA approves PGEN's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regulator's nod

** Papzimeos is approved to treat recurrent respiratory papillomatosis (RRP)—a condition that causes growth of wart-like tumors in the respiratory tract due to human papillomavirus (HPV) infection

** Up to last close, stock had risen 65.2% YTD